



**EuroTEST**

Working together for integrated  
testing and earlier care

*Addressing Hepatitis, HIV, STIs and TB*

# **EuroTEST Initiative**

## **Annual Report 2023**

## Contents

Introduction .....	3
Project activities, progress and results in 2023 .....	4
European Testing Week, including European Test Finder .....	4
HepHIV Conference 2023 .....	8
Mapping of HIV and hepatitis testing consent requirements in Europe .....	9
Working groups to review the definitions of HIV and viral hepatitis late diagnosis.....	9
Collaboration with diagnostic companies .....	10
Country support for prevention and control of HIV/AIDS, STIs and viral hepatitis in the EU/EEA countries.....	10
Policy and advocacy activities .....	11
European Standards of HIV prevention and care in the EU/EEA countries.....	12
List of EuroTEST-related publications and other media outputs in 2023 .....	13
Annex 1. Financial statement and EuroTEST Steering Committee .....	15

## Introduction

The EuroTEST Initiative (originally named HIV in Europe) began in 2007 as a way of bringing attention to the importance of earlier diagnosis and care for people living with HIV and has played a critical role in the HIV response by uniting clinicians, community activists, policy makers and researchers to ensure that people are diagnosed early and linked to care and treatment.

In 2013, a concerted effort was made to also prioritise hepatitis and in 2019 the disease scope was further broadened to also address sexually transmitted infections (STIs) and tuberculosis (TB). With this change, EuroTEST reflected parallel shifts in the field to address infectious diseases more broadly and in a less disease specific manner, mainly due to overlaps in modes of disease transmission and affected populations. The initiative's primary focus remains on integrated testing, when appropriate, and linkage to care for people with HIV, hepatitis B and C, TB and STIs, aiming to utilise integrated strategies to help increase early detection and earlier entry into treatment for better health outcomes and prevention of onward transmission.

Since its initiation, EuroTEST has built a European platform where a wide range of independent experts from civil society, policy institutions, health care and European public health institutions work toward influencing policy, share knowledge, and build the evidence-base to support earlier diagnosis and care.

The initiative is directed by a Steering Committee (SC), which is an independent group of HIV, viral hepatitis, STI and TB experts who represent civil society, research institutions, policy bodies, health systems and public health institutions, including representatives from the WHO Regional Office for Europe, the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The SC is led by two co-chairs, one clinical and one community representative.

EuroTEST's Policy Secretariat is based at the European AIDS Treatment Group (EATG) in Brussels. The Coordination Secretariat which oversees the day-to-day management of the initiative and its various projects including the financial management is based at Centre of Excellence for Health, Immunity and Infections (CHIP) at Rigshospitalet in Copenhagen, a hospital within the legal entity of the Capital Region of Denmark.

## Project activities, progress and results in 2023

### European Testing Week, including European Test Finder

Being one of the EuroTEST flagship projects, the European Testing Week ran for its eleventh consecutive year and celebrated its 10-year anniversary. European Testing Week (ETW) has become a well-known awareness campaign throughout Europe. The main aim of ETW is to unite partner organisations throughout Europe twice a year in Spring (May) and Autumn (November) to increase access to testing and increase awareness on the benefits of earlier hepatitis and HIV testing. The roughly 800 participants consist of a mix of community organisations, healthcare institutions, government and policy bodies as well as academia. Each organisation who participates in ETW volunteers their own time and resources to organise local campaign activities.



A working group, consisting of experts within HIV and viral hepatitis, provides advice and direction for the initiative.

The campaign secretariat is leading the promotion of the campaign and produces campaign materials, newsletters and social media content to support the participating organisations and institutions. Each campaign is being monitored and evaluated.

Key ETW activities in 2023 are described below:

### Strategic development of European Testing Week

In 2023 there has been a focus on increasing collaboration with regional networks, based on the 2022 face-to-face strategy meeting and discussions on how effectively to expand the reach and impact of the campaign. Efforts have been made to ensure representation of relevant regional networks; and following a review of the working group composition networks for migrant populations, transgender populations, prison populations, and networks from Eastern Europe were invited to appoint representatives for the ETW working group. The networks have provided input to the campaign topics ensuring that the messages of the campaign were relevant, and they have increasingly throughout the year disseminated information about ETW.

With the long-standing civil society chair of the working group (Ben Collins, ReShape, UK) stepping down, the ETW working group and the EuroTEST Steering Committee nominated candidates for this post, after which the Steering Committee elected a new civil-society co-chair (Tom Platteau from the Institute of Tropical Medicine in Antwerp, Belgium).

## Publication and promotion of the campaign on social media



The results of a special survey, carried out in 2022 among all current and former ETW participant to assess the use and impact of the campaign, were presented in a manuscript that was published in *HIV Medicine* in September (<https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.13544>).

As an effort to encourage more clinicians to participate in the campaign, promotion of ETW took place at the European AIDS Clinical Society (EACS) conference in Warsaw in October.

Social media activities continued in 2023 to focus on dissemination of ETW and related activities. ETW has its own accounts on X, Facebook, Instagram and YouTube (with the latter mainly being used for recordings of ETW webinars, partner endorsement videos promoting ETW and the European Test Finder (<https://www.youtube.com/@EuroTestWeek>)).

The Instagram account (set up in 2022) has been used actively by campaign



participants. Participants have posted their activities on their social media accounts and tagged the ETW account, and all posts have highlighted campaign activities across Europe. Various promotional content has been created by the secretariat including information about the Spring and Autumn campaigns, activities organised by the secretariat, and videos recorded by key stakeholders (including ECDC, World Hepatitis Alliance and members of the ETW working group) expressing support for the campaign. Posts have been boosted to reach a wider audience. Campaign participants were encouraged to include the campaign hashtags #EuroTestWeek and #TestTreatPrevent in their social media posts, to increase visibility of the campaign.

The Spring European Testing Week was held 15-22 May 2023, with 126 organisations signed up on the website as participants (although many more participated without signing up and published campaign posts on social media, downloaded our campaign materials, etc.).

The Working Group developed the Theme Statement highlighting current challenges and issues related to testing with a specific focus on the importance of strengthening collaboration among viral hepatitis, HIV and





STI networks and key population networks of people living with or affected by these infectious diseases.

The Spring ETW was launched at an event in Athens, Greece organised jointly by ETW, EODY (the Greek national public health organization), the Greek patient organisation Positive Voice, European AIDS Clinical Society, World Hepatitis Alliance and European AIDS Treatment Group. A joint press release was developed and disseminated leading up to the event. The meeting was streamed online and followed by a successful face-to-face roundtable discussion among Greek stakeholders from different sectors on how to improve testing for HIV, viral hepatitis and STIs.




The European Center for Disease Prevention and Control (ECDC) hosted a European Testing Week webinar on “HIV, Hepatitis B and C and Sexually Transmitted Infections: why is testing important and what can be done to increase testing access and uptake?”. 112 people joined the webinar, which received very positive feedback.

**The November European Testing Week** took place 20-27 November 2023. 141 organisations and institutions signed up as participants on the website. The November ETW marked the 10-year anniversary of ETW which was celebrated in several ways:

- A special anniversary logo was developed, and new campaign materials were branded with this logo (t-shirts, temporary tattoos, leaflets etc.).
- At the HepHIV conference (organized by EuroTEST) in Madrid in November, the opening reception included a speech by ETW's co-chairs and entertainment.



- The chair of the ETW working group presented the results of the ETW impact survey in one of the abstract-driven sessions of the conference and the presentation was followed up by an open side-meeting about ETW for all conference participants.
- ETW had its own booth at the conference with campaign materials, a slide show, roll-ups, a quiz about ETW, ETW t-shirts and ETW temporary tattoos. The booth attracted conference participants who were interested in learning about the campaign and the European Test Finder.
- The Theme Statement for November ETW highlighted the role of stigma and discrimination as barriers to testing (also the main focus of the Spanish EU presidency and the HepHIV conference). The statement included resources, and tools for addressing HIV and hepatitis-related stigma.
- To re-engage European politicians in prioritising efforts to end HIV, viral hepatitis and STIs as public health threats, a meeting was organised in the European Parliament on 29 November. The meeting was co-organised by UNITE Parliamentarians Network for Global Health, European AIDS Clinical Society, World Hepatitis Alliance, and European AIDS Treatment Group, and hosted by Portuguese Member of Parliament Sara Cerdas from the S&D Group. Stefan Schreck from the European Commission's Directorate-General for Health and Food Safety delivered a keynote speech.



### European Test Finder ([www.testfinder.info](http://www.testfinder.info))

European Test Finder (ETF) further expanded its reach in 2023 as more European testing sites registered their services on this online tool, which allows people to search for the nearest place to test for HIV, viral hepatitis or STIs. The number of services increased from 677 in January to 754 by December.

Different promotion videos were developed and shared on EuroTEST and ETW social media channels to encourage testing providers to register on the website and to promote the website to people in search of testing services.

Both ECDC and WHO Regional Office for Europe have assisted with this promotion of the European Test Finder and are linking people to it from their own websites.

ETW has during 2023 collaborated with different dating apps (Hornet and Grindr) who provided free promotion of the website to their users in connection with the Spring and Autumn campaign. This collaboration was successful and resulted in a huge increase in traffic on the website. During the Spring campaign, inbox messages promoting the Test Finder were delivered to 191,345 Hornet users, of which 1,893 actively visited the Test Finder. In the November campaign, there were 18,244 visits directed from inbox messages to Grindr users.

As a way of accommodating information on the quality of the testing services, the feature of linking to Google reviews of each of the testing services has been added to the Test Finder in 2023.

During ETW, the Test Finder was heavily promoted by the secretariat, collaborating dating app partners and ETW participants. This resulted in a remarkable increase in people searching for testing sites: during the week preceding ETW, there were 282 visits, while visits during the week of ETW surged to 19,623 visits, constituting an increase of 6,858%.

### HepHIV Conference 2023

The eighth HepHIV 2023 conference was held from 13-15 November 2023 in Madrid Spain in connection with the Spanish EU presidency. The conference



was attended by 185 participants from 32 countries. Of the attendees, 41% were community representatives, 22% were policymakers/public health institution representatives; 16% were clinicians, 8% represented social scientists, epidemiologist, statisticians and 13% represented 'other'.

The main theme of the Conference was on Stigma as well as progress and implementation of integrated testing, new technologies and ensuring equity in the delivery of HIV, viral hepatitis and STI services especially for mobile populations and migrants.

The scientific programme was structured into 5 plenary sessions, 4 abstract-driven session and 3 poster sessions. The programme and discussions showcased an abundance of research and interventions that effectively addressed prevention, testing and linkage to care for multiple infectious diseases and provided successful examples of clinical and community-based testing services from across Europe effectively providing trustworthy, culturally sensitive and stigma-free environments for migrants and mobile populations. The recorded presentations can be found on the conference [website](#).

An overall theme from the conference centered around the need to address HIV-related stigma and discrimination as a key structural barrier preventing Europe from meeting the Sustainable Development Goals (SDGs) and UNAIDS targets for 2030. Further, issues of implementation of integrated responses to HIV, viral hepatitis and STIs and TB and a need to strengthen collaboration between governments and implementers around testing and linkage to care was highlighted as an area still needing a strong focus.



Participants were invited to evaluate the conference in the conference App. Overall participants reported high satisfaction with the conference. 94% were satisfied with the conference and said it met their expectations, 96% agreed that the scientific programme was interesting and informative and relevant to their field of work and/or current research. A prioritisation from a previous HepHIV conference was to ensure time for discussions and social networking opportunities, and the evaluation results demonstrated that the HepHIV2023 had succeeded with this.

HepHIV2023 concluded with a conference 'Call to Action' covering six specific areas for action addressing the continued needed focus in policy and implementation agendas in the area of earlier and integrated testing for HIV, viral hepatitis STI and TB. The Call will upon completion be available on the conference website and EuroTEST is together with the conference national co-chairs working on a manuscript.

### Mapping of HIV and hepatitis testing consent requirements in Europe

Consent requirements for blood borne virus testing vary across European countries and tend to differ between HIV and viral hepatitis. Explicit informed consent accompanied by pre- and post-test counselling is recommended for HIV testing in many countries. In others, a written consent is required. Complicated HIV testing consent procedures are a barrier for testing implementation in many settings, particularly in non-specialist healthcare settings. Also, international testing guidelines, including from WHO and ECDC, do not recommend written consent and individualised pre-test counselling as pre-requisites for HIV testing. A comprehensive overview of European testing consent requirements for blood borne viruses appears to be lacking.

In 2023, a EuroTEST working group conducted a mapping and a [survey of HIV and viral hepatitis testing consent requirements](#) in the countries of the WHO European Region. The survey mapped differences between consent requirements for HIV and viral hepatitis testing, covering both policy and practice, including whether testing requires a written consent, documented oral consent, undocumented oral consent or is done as opt-out testing. Preliminary results were presented at meetings in late 2023 and a conference abstract will be submitted in spring 2024.

### Working groups to review the definitions of HIV and viral hepatitis late diagnosis

**HIV late diagnosis:** Late diagnosis and linkage to care of people living with HIV remains a key challenge in the response to the epidemic in Europe and elsewhere. The 2011 consensus definition of HIV late presentation was [revised](#) in 2022 by a EuroTEST working group to enable better distinction between people diagnosed late from those who acquired HIV recently and were misclassified as late due to an interim low CD4 cell count ( $\leq 350$  cells/ml blood). The revised definition proposes a hierarchy of markers of recent infection (i. laboratory evidence of recent infection; ii. a last negative HIV test within 12 months of HIV diagnosis; or iii. clinical evidence of acute infection) to facilitate re-categorisation of people recently infected as 'not late'.

In 2023, the working group initiated preparations for a multi-country pilot implementation study to apply the revised definition and estimate country specific correction factors to be applied to current surveillance data on late diagnosis, seeking to re-categorise people who are recently infected as 'not late' and adjust for the current overestimation of the proportion of people diagnosed late. The aim of

the pilot is also to generate experience from applying the definition in countries with different availability of the required markers.

Countries that previously indicated interest in participating in the pilot (through a survey conducted in 2022 on the availability of data on the required markers) met in Sevilla, Spain, on 13 September 2023 to discuss the preferred process for data compilation/collection, analysis, and other considerations regarding their participation in the study. An updated plan for the work and next steps was subsequently prepared for implementation in 2024.

**Chronic viral hepatitis late diagnosis:** An expert group under EuroTEST in 2017 developed a consensus definition of late presentation with chronic viral hepatitis to help improve epidemiological understanding of viral hepatitis. This definition is however not able to adequately differentiate between patients diagnosed at a late stage of infection and patients who have lived with diagnosed viral hepatitis for many years but are presenting late for care with advanced decompensated cirrhosis. To facilitate generation of valid data for assessing late diagnosis with chronic viral hepatitis, a EuroTEST working group has updated the definition to reflect this difference in patients. A manuscript on the revised definition has been drafted and will be consolidated, published and disseminated in 2024 to promote its use among relevant expert and research groups.

### Collaboration with diagnostic companies

As part of the November 2023 European Testing Week, a collaboration was set up with Cepheid where a number of European Testing Week participants could borrow free GeneXpert testing systems during the week. Cepheid provided free training and guidance to providers using the machines and two videos were produced.

### Country support for prevention and control of HIV/AIDS, STIs and viral hepatitis in the EU/EEA countries.

As part of an ECDC country support framework contract, EuroTEST in collaboration with the European AIDS Clinical Society (EACS) and Centre for Online and Blended Learning (COBL) at the University of Copenhagen have conducted two webinars, two online trainings, two face-to-face(F2F) trainings and one online follow-up session during 2023.

The overall aim of the two online webinars organised by EuroTEST, EACS and ECDC was to strengthen EU/EEA countries' capacities and capabilities to address the two different topics. The webinar on 'Improving testing for HIV and related co-infections in general practice' included presentations on common HIV-indicator conditions, co-infections, and ECDC integrated HIV, HBV and HCV testing guidance. Key focus was placed on the implementation and effectiveness of HIV-indicator condition testing. The webinar on 'Stigma: what you as a healthcare provider can do to address it' included presentations on defining stigma in the context of HIV, viral hepatitis and STIs, preliminary findings from the first European-wide



HIV Stigma Survey and both community and healthcare provider perspectives on overcoming stigma in healthcare settings. The two webinars each lasted for 60 minutes and had between 114 and 144 participants. Recordings of the two webinars are available on the [ECDC online virtual academy \(EVA\)](#) platform.

The aim of the two 1-day online trainings was to support the implementation of specific ECDC guidance. The first online training 'Implementing PrEP operational guidance: from guidelines to practice' took place over two half-days. 32 representatives from 19 EU/EEA countries participated. The second online training 'Implementing antenatal screening for HIV, hepatitis B and syphilis: from guidelines to practice' had 18 representatives from 17 EU/EEA countries.

The aim of the two FTF workshops was to improve the knowledge and technical capacities of public health professionals and civil society organisations working within or across HIV, viral hepatitis and STIs at the national/regional level to use ECDC surveillance and monitoring data/reports and tools. 14 representatives from Greece, Italy, Portugal and Spain attended the first workshop, while 17 representatives from Bulgaria, Hungary, Poland and Romania attended the second workshop. The FTF workshops were hosted over two working days at the ECDC headquarters in Stockholm, Sweden. As an outcome of the workshops, participants developed and presented a country-specific 'data for impact plan' with concrete next steps to address national data surveillance and monitoring challenges.

The aim of the 10 October 2023 online follow-up session was to continue supporting the implementation of ECDC HIV and viral hepatitis testing guidance as well as STI testing standards in an integrated manner in EU/EEA countries. 64 representatives from 14 EU/EEA countries participated. The online session included within-country group work sessions where participants discussed progress and alignment with their previously drafted 2022 country roadmap. Participants presented on their refined roadmap goals, good practices that have led to progress and barriers to address moving forward.

### Policy and advocacy activities

EuroTEST aims to inform policy processes, share knowledge, and improve the evidence base related to earlier testing and care. As part of its role as secretariat for policy and advocacy, the European AIDS Treatment Group (EATG) advocates for optimal testing and care for the EuroTEST initiative and promotes its project findings to stakeholders.

Sustained advocacy by EuroTEST and partners for EU health funding and focus on addressing testing and linkage to care for HIV, TB, viral hepatitis for key populations have in 2023 especially been highlighted in the meeting in the European Parliament in November. As described above the meeting was hosted by Portuguese Member of Parliament Sara Cerdas from the S&D Group and Stefan Schreck from the European Commission's Directorate-General for Health and Food Safety delivered a keynote speech. A follow-up meeting is planned for 2024.

Further, EuroTEST has both presented and been represented at multiple European meetings and conferences in 2023, including:

- The European Economic and Social Committee (EESC) public hearing on Measures to fight stigma against HIV, organiser: European Economic and Social Committee, participation on behalf of the European Testing Week working group (29 March 2023);
- Fast Track City 'Cohort of Champions - webinar on HIV testing and Diagnosis', presentation on 'Gap analysis on testing: what needs to be addressed' (12 May 2023, online);
- 1st Central and Eastern Europe Fast-Track Cities Workshop, Vienna, presentation entitled "Maybe scaling up testing is not enough? Overcoming late diagnosis and presentation of HIV" (12 June 2023);
- ECDC and WHO/Europe HIV network, Sevilla, Spain (13-14 Sept 2023);
- HepHIV Conference, Madrid, open European Testing Week side meeting, organized by EuroTEST (13-15 Nov 2023);
- HepHIV Conference, Madrid, ETW oral presentation on "Increasing testing for HIV and hepatitis through European Testing Week - lessons learned from 10 years of a regional awareness campaign" (13-15 Nov 2023);
- European Parliament event, organized by EuroTEST and co-organized by UNITE parliamentarians network for global health, EACS, World Hepatitis Alliance and EATG, entitled "10 years of European Testing Week, Progress and gaps - a call to action to end HIV, viral hepatitis & STIs in Europe" (29 Nov 2023).

### European Standards of HIV prevention and care in the EU/EEA countries

As a related activity, CHIP has in 2023 in collaboration with the European AIDS Clinical Society (EACS) developed the first two Standard of Care Modules on HIV Testing and Pre-exposure prophylaxis (PrEP) under the ECDC framework contract on European Standards of HIV Care.

The Standards have been developed with a team of scientific experts consisting of clinical, public health and community experts and designed for three distinct groups: people either at risk of HIV acquisition or already living with HIV; people responsible for the provision and delivery of services; and those who have responsibility for commissioning and or funding of services.

During 2024, CHIP will coordinate the development of 3 new modules focusing on Antenatal screening, Commencement of ART and HIV and co-morbidities and develop an online audit tool for auditing on of the two first developed Standards (TBD). The work will be presented at the EACS Standard of Care meeting in October 2024.

## List of EuroTEST-related publications and other media outputs in 2023

### Publications

1. Raben D, Kahama CB, Combs L, Stengaard A, Rockstroh JK, Simões D, Collins B; European Testing Week Working Group and the EuroTEST Steering Committee. The use and impact of European Testing Week regional awareness campaigns to increase HIV and viral hepatitis testing coverage. HIV Med. 2023 Sep 29. doi: 10.1111/hiv.13544.

### Presentations/Posters

1. Collins B, et al, for the European Testing Week Working Group. Increasing testing for HIV and hepatitis through European Testing Week - lessons learned from 10 years of a regional awareness campaign. HepHIV 2023 conference, Madrid, Spain, 15 November 2023.
2. Collins B et al, for the European Testing Week Working Group. Maybe scaling up testing is not enough? Overcoming late diagnosis and presentation of HIV. 1st Central and Eastern Europe Fast-Track Cities Workshop, Vienna, Austria 12 June 2023.
3. Raben D. Gap analysis on testing: what needs to be addressed. Fast Track City 'Cohort of Champions - webinar on HIV testing and Diagnosis', 12 May 2023 (online).
4. Collins B, et al, for the European Testing Week Working Group. How a European Commission-supported campaign – ETW – has supported integrated testing in Europe. Spring ETW launch event “Bringing networks together to increase testing for HIV, viral hepatitis and STIs, Athens, Greece and online, 15 May 2023.

### Webinars, videos and other media outputs

#### Webinars:

1. European Testing Week. Spring 2023. Webinar/live event in Athens: “Bringing networks together to increase testing for HIV, viral hepatitis and STIs”. Available from <https://www.testingweek.eu/resources/webinars-videos/>
2. European Testing Week. Spring 2023. Webinar (hosted by ECDC): “HIV, Hepatitis B and C and Sexually Transmitted Infections: why is testing important and what can be done to increase testing access and uptake?”. Available from <https://www.testingweek.eu/resources/webinars-videos/>
3. European Testing Week. Autumn 2023. Live streaming of meeting at the European Parliament “10 years of European Testing Week. Progress and gaps – a call to action to end HIV, viral hepatitis & STIs in Europe”.

#### Videos:

1. European Testing Week. SETW 2023. Support videos from Teymur Noori (EDCD), Rachel Halford (World Hepatitis Alliance), Jorge Garrido (Apoyo Positivo), Tom Platteau (Institute of Tropical Medicine, Antwerp). Available from: <https://www.youtube.com/channel/UCmyMeow2Re-Bo8S8f1rfZtg>
2. European Test Finder. It's time to get tested! Available from: <https://www.youtube.com/shorts/7Zifugut9r>
3. European Testing Week. What is European Testing Week? Available from: <https://www.youtube.com/shorts/kbWfLaXXfiQ>



Other media:

1. Spring statement from the European Testing Week working group: “Strengthening our collaborations among hepatitis/HIV/STI/TB prevention and key population networks. Available from: <https://www.testingweek.eu/campaign-materials/statements/>.
2. November statement from the European Testing Week working group: “Stigma and discrimination are barriers to testing – you can help change that!”. Available from: <https://www.testingweek.eu/campaign-materials/statements/>
3. See other media outputs on the European Testing Week [YouTube channel](#), [Facebook page](#), [Instagram page](#), and [Twitter page](#).

**ECDC country support activities, jointly with EACS**

1. Webinar: ‘Improving testing for HIV and related co-infections in general practice’. [ECDC online virtual academy \(EVA\)](#)
2. Webinar: ‘Stigma: what you as a healthcare provider can do to address it’. [ECDC online virtual academy \(EVA\)](#)

## Annex 1. Financial statement and EuroTEST Steering Committee

### Financial statement

The EuroTEST initiative has received funding and grants from Gilead Sciences, ViiV Healthcare, Merck/MSD, Cepheid and the European Centre for Disease Prevention and Control (ECDC).

The HepHIV 2023 Conference has applied for sponsorship grants for this purpose via the EuroTEST Initiative from Gilead Sciences, MSD/Merck and ViiV Healthcare.

### EuroTEST Steering Committee

Members: Ann K. Sullivan, Chelsea & Westminster Hospital, United Kingdom; Ben Collins, European Testing Week working group chair, ReShape/International HIV Partnerships, United Kingdom; Brian Gazzard, Imperial College, School of Medicine, HIV Research Director, Chelsea & Westminster Hospital, United Kingdom; Cary James, World Hepatitis Alliance, United Kingdom; Daniel Simões, Coalition PLUS, Portugal (Chair); Daniela Rojas Castro, Coalition PLUS, France; Ferenc Bagyinszky, AIDS Action Europe, Germany; Francesco Negro, European Association for the Study of the Liver (EASL), Switzerland; Igor Karpov, Department of Infectious Disease, Belarus State Medical University, Belarus; Irith De Baetselier, Antwerp Institute of Tropical Medicine, Belgium; Jack S. Lambert, University College Dublin (UCD), Ireland; Jens D. Lundgren, Rigshospitalet, CHIP (Centre of Excellence for Health, Immunity and Infections), University of Copenhagen, Denmark; Johanna Brännström, Department of Infectious Diseases, South Hospital & Institute of Medicine, Karolinska Institute, Stockholm, Sweden; Jordi Casabona, Center for HIV/STI Epidemiological Studies of Catalonia (CEEISCAT), Spain; Jürgen Rockstroh, Department of Medicine I, University Hospital Bonn, Germany (Chair); Olesia Murha, TB Coalition Europe, Ukraine; Lella Cosmaro, Fondazione LILA Milan, Italy; Liudmyla Maistat, Medicines Patent Pool, Switzerland; Liver Patients International (name TBC); Magnus Unemo, WHO Collaborating Centre for Gonorrhoea and Other STIs, National Reference Laboratory for STIs, Örebro University Hospital, Sweden; Mojca Matičič, University Medical Centre Ljubljana, Slovenia; Nikos Dedes, European AIDS Treatment Group (EATG) & Positive Voice, Greece; Nino Tsereteli, Center for Information and Counseling on Reproductive Health – Tanadgoma, Georgia; Rajul Patel, Department of Genitourinary Medicine, Southampton University Hospitals & International Union against Sexually Transmitted Infections (IUSTI), United Kingdom; Tom Platteau, HIV/STI clinic of the Institute of Tropical Medicine in Antwerp, Belgium; Valerie Delpech, New South Wales Health, Sidney, Australia; Yazdan Yazdanpanah, Director, ANRS Maladies Infectieuses Emergentes, France.

Observers: European Centre for Disease Prevention and Control (ECDC) Anastasia Pharris; European Monitoring Centre for Drugs and Drug Addiction (EMDCCA) Thomas Seyler; World Health Organization Regional Office for Europe, Stela Bivol, Viatcheslav Grankov; WHO HQ Geneva: Antons Mozalevskis, Elena Vovc.

### European Testing Week Working Group members

Alexandra Smith, World Hepatitis Alliance; Amanita Calderon-Cifuentes, TGEU; Anna Koshikova, Eurasian Movement for the Right to Health in Prisons; Anna Zakowicz, Independent expert; Ann-Isabelle Von Lingen, EATG (European AIDS Treatment Group) (EuroTEST Policy Secretariat); Ann Piercy, HIV Ireland; Bart-Jan Mulder, GGD Amsterdam (Health Dep of Amsterdam); Ben

Collins, ReShape/International HIV Partnerships; Cary James, World Hepatitis Alliance; Daniel Kashnitsky, Regional Expert Group on Migration and Health for Eastern Europe and Central Asia; Denis Onyango, Africa Advocacy Foundation; Georg Bröring, Correlation European Harm Reduction Network (C-EHRN); Igor Gordon, Eurasian Harm Reduction Association; John (Jack) S Lambert, University College Dublin; Jason Farrell, Correlation Network/Choices Support Center; Jorge Garrido, Apoyo Positivo; Josip Begovac, EACS; Katrin Schiffer, Correlation European Harm Reduction Network (C-EHRN); Laura Fernandez-Lopez, Center for HIV/STI Epidemiological Studies of Catalonia (CEEISCAT); Magdalena Ankiersztejn-Bartczak (co-chair), Foundation for Social Education; Marine Gogia, Georgian Harm Reduction Network; Milan Mishkovikj, ELPA; Nenad Micov, EATG (European AIDS Treatment Group); Nikolay Lunchenkov, ECOM; Nikos Dedes, Positive Voice; Sini Pasanen, HIV Finland; Takudzwa Mukiwa, Terence Higgins Trust; Tom Platteau (co-chair), HIV/STI clinic of the Institute of Tropical Medicine in Antwerp; Valerie Delpech, Independent Public Health consultant; Zoran Dominković, ISKORAK; Anastasia Pharris, ECDC;